The future of therapeutics capable of treating, curing, and even entirely preventing many previously life-threatening illnesses has arrived! Whether it is developing drugs for molecular targets rather than specific diseases, replacing/correcting specific genes, or introducing cells engineered with bespoke features or payloads, a new dawn is upon us. For business development leaders this presents unusual and unprecedented challenges. How do unproven development pathways, uncertain and fluctuating markets sizes, and the potential for value-based pricing and payments affect how deals are negotiated and structured? Join us for a discussion among biopharma business development and finance leaders in this emerging space as they share their thoughts on creating value through business and corporate development activities in the context of the radical new technologies that are changing the practice of medicine.